Thymosin β4 and Actin: Binding Modes, Biological Functions and Clinical Applications.
Level 5 - mechanism / opinion, no new human data
Narrative review detailing molecular mechanisms and theoretical clinical applications without systematic review or original human data
PubMed 36464872 · doi:10.2174/1389203724666221201093500
What was done
This narrative review synthesized recent literature regarding the molecular mechanisms, actin-binding dynamics, pharmacological actions, and therapeutic applications of thymosin β4 (Tβ4).
What was found
The abstract reports no clinical trial results or quantitative efficacy metrics. It notes that Tβ4 accounts for roughly 70% to 80% of β-thymosins in human cells and binds G-actin in a 1:1 ratio to inhibit polymerization and control F-actin treadmilling. It outlines theoretical and preclinical roles for Tβ4 in regulating inflammation, angiogenesis, organ preservation (heart, liver, kidney, brain, intestine), and tissue regeneration (cornea, skin trauma, hair follicles, bone, and teeth).
Why it matters
The paper summarizes the structural and mechanistic rationale for how Tβ4 regulates cell motility and cytoskeleton dynamics, outlining potential therapeutic targets for tissue repair.
Limits
The abstract describes a broad narrative overview without systematic search criteria, meta-analytic pooling, study quality appraisal, or specific clinical trial outcome data.
Cited by
- supports Thymosin beta-4 stimulates angiogenesis and tissue repair.